Volume : 09, Issue : 06, June – 2022
13.INCIDENCE AND PREVALENCE OF MUCORMYCOSIS IN COVID -19 PATIENTS WITH COMORBID CONDITIONS IN TERTIARY CARE HOSPITAL
J. Hindu Priya, V. Ramya Sri, S. Akhila, Lateef Begum, Dr. L. Kiran Kumar Reddy
Aim: The aim of the study carried out was to check the Incidence and prevalence of Mucormycosis in covid-19 patients with comorbid conditions.
Methodology: This is the retrospective observational study conducted in the In-patient department of the Covid-19 ward at Aware Global Hospital and Govt. ENT Hospital, the relevant data on the Drug prescription of each patient was collected from Medical Record Department, patient age, sex, diagnosis, treatment, drugs, doses of drugs, frequency of drugs, and route of administration were collected.
Results: A total number of 100 patients with mucormycosis were enrolled in the study, of which 80 were male patients and there were 20 female patients. The study revealed that hypertension is the second leading factor for Covid-19 associated with Mucormycosis. 1/4th of the patients have developed Denovo diabetes due to administration of steroids, were as 1/5th of the patients have both diabetes and hypertension.
Conclusion: The study concludes that most of the patients with a history of diabetes and hypertension were detected during the study period. Mostly males were affected, due to over usage of steroids few patients are affected with Denovo diabetes.
Cite This Article:
Please cite this article in press J.Hindu Priya et al., Incidence And Prevalence Of Mucormycosis In Covid -19 Patients With Comorbid Conditions In Tertiary Care Hospital.,Indo Am. J. P. Sci, 2022; 09(6).,
Number of Downloads : 10
1) Dyer O (May 2021). “Covid-19: India sees record deaths as “black fungus” spreads fear”. BMJ. 373: n1238. doi:10.1136/bmj.n1238. PMID 33985993. Quarterly Current Affairs Vol. 4 – October to December 2020 for Competitive Exams. Vol. 4. Disha Publications. 2020. p. 173. ISBN 978-93-90486-29-8.
2) icd.who.int. Retrieved May 25, 2021. Jump up to a b c d e f g h i j “About Mucormycosis”. www.cdc.gov. May 25, 2021
3) Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives [Internet]. Vol. 54, Clinical Infectious Diseases. Clin Infect Dis; 2012 [cited 2021 May 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/22247451/
4) Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis, and treatment. Clin Microbiol Infect [Internet]. 2004 [cited 2021 May30];10(SUPPL.1):31–47.Available https://pubmed.ncbi.nlm.nih.gov/14748801/.
5) Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, Chen J. Mucormycosis in renal transplant recipients: a review of 174 reported cases external icon. BMC Infect Dis. 2017 Apr; 17(1): 283.
6) Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudanexternal icon. J Clin Microbiol. 2002 Mar; 40(3): 1031–1036.
7) Vallabhaneni S, Mody RK. Gastrointestinal mucormycosis in neonates: a review external icon. Current Fungal Infect Rep. 2015.
8) Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in children: review and recommendations for management external icon. J Pediatric Infect Dis Soc. 2018 May 15;7(2):159-164.